• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket

    6/6/23 8:36:13 AM ET
    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Industrial Machinery/Components
    Technology
    Metal Fabrications
    Industrials
    Get the next $ACMR alert in real time by email

    Gainers

    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
    • Chijet Motor Company, Inc. (NASDAQ:TTOO) shares surged 51.3% to $0.1060 in pre-market trading after dipping around 31% on Monday. T2 Biosystems reported submission for the FDA breakthrough device designation for candida auris diagnostic test.
    • Secoo Holding Limited (NASDAQ:SECO) gained 35.8% to $1.100 in pre-market trading.
    • Zura Bio Limited (NASDAQ:ZURA) shares gained 35.4% to $8.79 in pre-market trading after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist.
    • Greenlane Holdings, Inc. (NASDAQ:GNLN) gained 29.5% to $0.36 in pre-market trading. Greenlane reported effectiveness of previously announced reverse stock split.
    • GitLab Inc. (NASDAQ:GTLB) shares rose 27.6% to $45.18 in pre-market trading following better-than-expected first-quarter results.
    • Regional Health Properties, Inc. (NYSE:RHE) shares climbed 25.8% to $3.78 in pre-market trading after gaining around 4% on Monday.
    • Mereo BioPharma Group plc - ADR (NASDAQ:MREO) rose 16.2% to $1.22 in pre-market trading. Ultragenyx and Mereo BioPharma reported data from ongoing Phase 2/3 Orbit study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI).
    • Bioventus Inc. (NASDAQ:BVS) rose 16% to $3.13 in pre-market trading after declining around 9% on Monday.
    • Coya Therapeutics, Inc. (NASDAQ:COYA) shares gained 13.5% to $4.77 in pre-market trading after declining 8% on Monday.

    Losers

    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) fell 39.6% to $1.01 in pre-market after dropping over 20% on Monday.
    • Pasithea Therapeutics Corp (NASDAQ:KTTA) shares dropped 35% to $0.33 in pre-market trading. Pasithea Therapeutics shares jumped 25% on Monday after Lucy Scientific Discovery proposed to acquire the company for $0.60 per share in cash and $0.25 per share in Lucy stock.
    • Sono Group N.V. (NASDAQ:SEV) fell 15.7% to $0.2569 in pre-market trading after gaining around 76% on Monday.
    • View, Inc. (NASDAQ:VIEW) fell 13.5% to $0.1685 in pre-market trading. View announced plans for reverse stock split to ensure full compliance with Nasdaq listing rules.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 12.2% to $0.2002 in pre-market trading. Bluejay Diagnostics filed for mixed shelf of up to $25 million.
    • Ucommune International Ltd (NASDAQ:UK) shares dropped 11.5% to $0.8935 in pre-market trading after surging over 50% on Monday.
    • AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) fell 10.6% to $0.17 in pre-market trading after dropping 44% on Monday.
    • Ayro, Inc. (NASDAQ:AYRO) shares fell 10% to $0.50 in pre-market trading. AYRO, last month, reported a first-quarter sales decline of 89% Y/Y to $0.113 million, missing the consensus of $0.300 million.
    • ACM Research, Inc. (NASDAQ:ACMR) fell 8.5% to $8.90 in pre-market trading.
    • Timber Pharmaceuticals, Inc. (NYSE:TMBR) fell 8.5% to $1.72 in pre-market trading. Timber Pharmaceuticals shares jumped 26% on Monday following a positive decision from the FDA for its TMB-001 treatment.

     

    Now Read This: Dow Drops 200 Points But Investor Sentiment Improves

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AGRI
    $AYRO
    $BJDX

    CompanyDatePrice TargetRatingAnalyst
    GitLab Inc.
    $GTLB
    4/22/2026$27.00Buy → Neutral
    BofA Securities
    GitLab Inc.
    $GTLB
    4/20/2026$25.00Outperform → Sector Perform
    RBC Capital Mkts
    GitLab Inc.
    $GTLB
    4/16/2026$24.00Buy → Neutral
    UBS
    GitLab Inc.
    $GTLB
    4/9/2026Buy → Neutral
    Guggenheim
    Bioventus Inc.
    $BVS
    3/27/2026$14.00Market Outperform
    CJS Securities
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    GitLab Inc.
    $GTLB
    3/23/2026Outperform → Underperform
    William Blair
    Aptera Motors Corp.
    $SEV
    3/9/2026$10.00Buy
    Alliance Global Partners
    More analyst ratings

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GitLab Wins a 2026 Google Cloud Technology Partner of the Year Award for DevSecOps

    GitLab recognized as Application Development - DevSecOps partner All Remote - GitLab Inc., the intelligent orchestration platform for DevSecOps, today announced that it has received the 2026 Google Cloud Technology Partner of the Year Award in the Application Development - DevSecOps category. This is the sixth consecutive year GitLab has been recognized. Development teams are adopting AI agents faster than they can govern them. GitLab and Google Cloud expanded their collaboration to help address that gap so teams get the speed of AI-assisted development and the controls their organizations require. Building on a partnership that began in 2018, GitLab Duo Agent Platform uses Google Clo

    4/22/26 9:00:00 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    Kerrisdale and Steamboat Send Letter to ACM Research Inc.

    NEW YORK, April 22, 2026 /PRNewswire/ -- Kerrisdale Capital Management, LLC and Steamboat Capital Partners, LLC today sent a letter to the CEO and Board of Directors of ACM Research, Inc.  The full text of the letter follows:April 22, 2026David H. WangChief Executive OfficerACM Research, Inc.42307 Osgood Road, Suite IFremont, CA  94539cc: Board of DirectorsDear David,Kerrisdale Capital Management, LLC, Steamboat Capital Partners LLC and our respective affiliates collectively own or advise entities owning approximately 600,000 shares of ACM Research, Inc. We are excited to hear that management is taking preliminary steps to pursue a Hong Kong share listing, per your Form 8-K filed with the Se

    4/22/26 8:30:00 AM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    Greenlane Holdings Announces Upcoming Pre-Funded Warrant Conversion and Lock-Up of Strategic Advisor Warrants

    Berachain Investment Corporation to Convert 33,085 of 1,476,464 Pre-Funded Warrants to Remain Within Contractual Beneficial Ownership Limitations;  Select Strategic Advisor Warrant Holders Agree to a Lock-Up until April 2027 BOCA RATON, Fla., April 21, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a publicly traded digital asset treasury company with a strategic focus on BERA, the native digital asset of the Berachain blockchain network, today announced that the Berachain Investment Corporation ("BIC"), has notified the Company that it will be converting a portion of its pre-funded warrants ("Pre-Funded Warrants") into shares of the Compa

    4/21/26 5:00:00 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    SEC Filings

    View All

    Zura Bio Limited filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Zura Bio Ltd (0001855644) (Filer)

    4/23/26 4:50:58 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Bioventus Inc.

    DEFA14A - Bioventus Inc. (0001665988) (Filer)

    4/22/26 7:54:50 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Bioventus Inc.

    DEF 14A - Bioventus Inc. (0001665988) (Filer)

    4/22/26 7:51:42 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pappis Charles C

    4 - ACM Research, Inc. (0001680062) (Issuer)

    4/21/26 4:30:08 PM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    SEC Form 4 filed by Johnson Michael Edious

    4 - Aptera Motors Corp (0001786471) (Issuer)

    4/21/26 2:28:38 PM ET
    $SEV
    Auto Manufacturing
    Industrials

    SEC Form 3 filed by new insider Coastlands Capital Lp

    3 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    4/17/26 9:45:12 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GitLab downgraded by BofA Securities with a new price target

    BofA Securities downgraded GitLab from Buy to Neutral and set a new price target of $27.00

    4/22/26 7:53:14 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    GitLab downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded GitLab from Outperform to Sector Perform and set a new price target of $25.00

    4/20/26 8:23:59 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    GitLab downgraded by UBS with a new price target

    UBS downgraded GitLab from Buy to Neutral and set a new price target of $24.00

    4/16/26 8:00:58 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ai Biotechnology Llc bought $12,500,000 worth of Class A Ordinary Shares (2,000,000 units at $6.25) (SEC Form 4)

    4 - Zura Bio Ltd (0001855644) (Issuer)

    3/2/26 5:55:03 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Staples William bought $124,750 worth of shares (3,276 units at $38.08), increasing direct ownership by 0.96% to 345,671 units (SEC Form 4)

    4 - Gitlab Inc. (0001653482) (Issuer)

    1/5/26 6:26:25 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Financials

    Live finance-specific insights

    View All

    ACM Research to Release First Quarter 2026 Preliminary Revenue Range on April 27, 2026 and Full Financial Results on May 7, 2026

    FREMONT, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR) announced today that it will release its preliminary revenue range for the first quarter of 2026 before the U.S. market open on Monday, April 27, 2026, to coincide with reporting obligations of ACM Research (Shanghai), Inc., ACM's principal operating subsidiary, to the Shanghai Stock Exchange. ACM will release its full financial results for the first quarter of 2026 before the U.S. market open on Thursday, May 7, 2026. ACM will conduct a corresponding conference call at 8:00 a.m. U.S. Eastern Time (8:00 p.m. China Time) to discuss the results. What:ACM First Quarter (ended March 31, 2026) Earnings

    4/15/26 4:05:00 PM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    GitLab Reports Fourth Quarter and Full Year Fiscal Year 2026 Financial Results; Board of Directors Authorizes $400 million for Share Repurchase Program

    Fourth Quarter Fiscal Year 2026 Highlights: Total revenue of $260.4 million, up 23% year-over-year GAAP operating margin of (2)%; non-GAAP operating margin of 21% Operating cash flow of $45.8 million and non-GAAP adjusted free cash flow of $41.8 million Fiscal Year 2026 Highlights: Total revenue of $955.2 million, up 26% year-over-year GAAP operating margin of (7)%; non-GAAP operating margin of 17% Operating cash flow of $232.9 million and non-GAAP adjusted free cash flow of $219.6 million -All-Remote-GitLab Inc. (NASDAQ:GTLB), the intelligent orchestration platform for DevSecOps, today reported financial results for its fourth quarter fiscal year of 2026, ended Janu

    3/3/26 4:05:00 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    ACM Research Reports Fourth Quarter and Fiscal Year 2025 Results

    FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced packaging applications, today reported financial results for its fourth quarter and fiscal year ended December 31, 2025. "2025 was a year of strong execution for ACM," said ACM's President and Chief Executive Officer, Dr. David Wang. "We delivered record annual revenue of $901 million, up 15% year over year, outperforming estimated China WFE. We strengthened our foundation for long-term growth by advancing new products, expanding our global production capacity, and enhancing global funding initiatives." Dr. Wang conti

    2/26/26 7:00:00 AM ET
    $ACMR
    Industrial Machinery/Components
    Technology

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Leadership Updates

    Live Leadership Updates

    View All

    Greenlane Reports Fourth Quarter and Full Year 2025 Financial Results

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a publicly traded digital asset treasury company focused on the acquisition, management, and strategic deployment of BERA, the native token of the Berachain blockchain network, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Digital Asset Treasury Strategy In October 2025, following the closing of a private placement that raised $110.7M in capital, Greenlane adopted a Treasury Policy and initiated a strategic shift toward a digital asset treasury strategy focused on BERA, the native token of the Berachain blockchain

    3/31/26 5:01:24 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Greenlane Provides Digital Asset Treasury Update: Completes Deployment of Approximately 50 Million Units of BERA

    Total holdings of approximately 70.4 million units of BERA as of February 27, 2026 Up to 50 million units of BERA deployed into validator infrastructure across multiple operators Jason Hitchcock appointed Chief Executive Officer to advance DAT strategy BOCA RATON, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN), a company with a Berachain-focused Digital Asset Treasury ("DAT"), is providing an update on its holdings of units of BERA and deployment activity. Digital Asset Treasury Holdings Update As of February 27, 2026, the Company held approximately 70.4 million units of BERA1. Since the Company's last treasury update on

    3/3/26 7:30:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $AGRI
    $AYRO
    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care